目的 观察中重度慢性阻塞性肺疾病急性加重期患者住院期间给予乌司他丁和胸腺肽免疫调节治疗，对患者肺功能 的影响。方法 2015年1月-2016年1月抽取住院慢性阻塞性肺疾病患者68例，随机分为常规治疗组(n=36)及免疫调节 组(n=32)。入院后两组患者均给予常规抗感染、平喘治疗等对症治疗，免疫调节组加用乌司他丁及胸腺肽免疫调节 治疗，比较两组患者在治疗前后血气分析PCO2、PO2变化，肺功能FEV1和TNF-a、IL-8炎症因子水平变化，及出院2 月后肺功能状态的比较。结果 免疫调节组治疗后肺功能FEV1(0.96±0.12)L较常规治疗组(1.47±0.09)L/ml明显增 加(P<0.05)；免疫调节组PCO2下降(46.47±5.07)mmHg较常规治疗组(52.34±4.21)mmHg明显下降；疗程结束后两组 患者血清TNF-a、IL-8、CRP炎症因子水平均较治疗前下降，免疫调节组血清TNF-a、IL-8下降水平较常规治疗组更 明显(P<0.05)。结论 免疫调节治疗可使显著改善AECOPD患者肺功能下降情况，可能通过抑制全身炎症水平机制达 到。

Objective To study the effect of thymosin α1 and Ulinastatin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Metheds 68 AECOPD patients were randomized divided into control group and treatment group. Control group received conventional treatment. Patients in the treatment group were treated with conventional treatment puls thymosin α1 and Ulinastatin. Results In treatment group PaO2, FEV1 volum were increased than control group (P<0.05). Serum TNF-α and IL-8 level intreatment group were decreased significantly than control group (P<0.05). Conclution Thymosin α1 and Ulinastatin treatment enhances AECOPD curative effect.